This article is more than 5 years old. Information may no longer be current.
Inspire discontinues macular edema drug trials
Click Here to Manage Email Alerts
DURHAM, N.C. — Inspire Pharmaceuticals has discontinued two phase 2 clinical trials of a drug the company was developing for the treatment of macular edema.
In a press release, the company said the two pilot trials of denufosol tetrasodium intravitreal injection were started in 2005.
One trial was to enroll 15 patients with persistent macular edema associated with uveitis. In the patients enrolled, there has been no demonstrable improvement either in reduction of retinal thickness or in visual acuity, Inspire said in the press release. In a second trial, which was to enroll 15 patients with persistent macular edema after cataract surgery, no patients have been enrolled.
The company has no plans to conduct any further studies of denufosol for the treatment of retinal disease, but it will continue to monitor treated patients for safety for a period of 1 year, the release said.